Consensus Spyre Therapeutics, Inc.

Stocks

SYRE

US00773J2024

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-10-02 EDT			5-day change	1st Jan Change
93.19 ^USD	+3.63%		+8.75%	+184.46%

09-09	Spyre Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10:00 AM
09-08	Spyre Therapeutics' SPY003 Meets Phase 2 Primary Endpoint in Ulcerative Colitis	MT

Evolution of the Average Target: Spyre Therapeutics, Inc.

Evolution of the Target Price: Spyre Therapeutics, Inc.

Changes in Analyst Recommendations: Spyre Therapeutics, Inc.

0c40cf8764023aef3.MI6LlDjb9-RlIHJz8VFCiKOwTMqIacXOYxHUP-O3O90.Ubzv7Uyuo64EFEsdgytx7uHGDpjCG4SHGinjRdvAfLVm1u3xfJ_HngwVFQ~cac35fc47da3c3d3056b0c8b8ce626ea

Analysts' recommendations: Spyre Therapeutics, Inc.

10-01	JPMorgan Initiates Spyre Therapeutics at Overweight With $110 Price Target	MT
08-26	U.S. research roundup- Intuit, MongoDB, Zscaler	RE
08-26	Spyre's IBD Pipeline Remains Key Driver, Wedbush Says	MT
08-26	Deutsche Bank Adjusts Spyre Therapeutics PT to $127 From $135, Maintains Buy Rating	MT
08-26	Wedbush Adjusts Price Target on Spyre Therapeutics to $123 From $130, Maintains Outperform Rating	MT
08-05	Wedbush Adjusts Price Target on Spyre Therapeutics to $130 From $100, Maintains Outperform Rating	MT
07-13	Mizuho Raises Price Target on Spyre Therapeutics to $120 From $84, Keeps Outperform Rating	MT
06-23	Deutsche Bank Adjusts Spyre Therapeutics Price Target to $135 From $115, Maintains Buy Rating	MT
06-15	Wedbush Raises Price Target on Spyre Therapeutics to $100 From $80 on Positive SPY002 Results, Maintains Outperform Rating	MT
06-15	Wedbush Raises Price Target on Spyre Therapeutics to $100 From $80, Maintains Outperform Rating	MT
06-04	Deutsche Bank Adjusts Spyre Therapeutics Price Target to $115 From $102, Maintains Buy Rating	MT
05-12	Deutsche Bank Adjusts Spyre Therapeutics Price Target to $102 From $86, Maintains Buy Rating	MT
04-14	Mizuho Boosts Price Target on Spyre Therapeutics to $84 From $53, Keeps Outperform Rating	MT
04-14	Deutsche Bank Adjusts Spyre Therapeutics PT to $88 From $55, Maintains Buy Rating	MT
04-13	Wedbush Adjusts Price Target on Spyre Therapeutics to $80 From $65, Maintains Outperform Rating	MT
02-23	Deutsche Bank Adjusts Spyre Therapeutics PT to $55 From $45, Maintains Buy Rating	MT
12-18	Mizuho Initiates Spyre Therapeutics at Outperform With $53 Price Target	MT
12-17	Citigroup Initiates Spyre Therapeutics at Buy With $64 Price Target	MT
11-06	Deutsche Bank Adjusts Spyre Therapeutics Price Target to $42 From $43, Maintains Buy Rating	MT
25-10-14	Spyre Therapeutics Inc - Expects $486.2 million in cash and equivalents as of Sept 30, 2025 - SEC filing	RE
25-09-26	Deutsche Bank Initiates Spyre Therapeutics at Buy With $43 Price Target	MT
25-04-08	Leerink Partners Initiates Spyre Therapeutics With Outperform Rating, $45 Price Target	MT
25-03-18	Wolfe Research Initiates Spyre Therapeutics at Outperform With $27 Price Target	MT
24-12-11	JonesTrading Initiates Spyre Therapeutics at Hold	MT
24-09-04	Wedbush Initiates Spyre Therapeutics at Outperform With $45 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	SPYRE THERAPEUTICS, INC.					+29%
	WUXI APPTEC CO., LTD.					+11.79%
	ARGENX SE					+27.75%
	LONZA GROUP AG					+21.67%
	REVOLUTION MEDICINES, INC.					+24.6%
	IQVIA HOLDINGS INC.					+11.82%
	BEONE MEDICINES AG					+21.07%
	CELLTRION, INC.					+46.63%
	WUXI BIOLOGICS (CAYMAN) INC.					+6.77%
	BIONTECH SE					+20.91%
	Average					+22.20%
	Weighted average by Cap.					+20.90%